SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 189 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,731 | -54.1% | 66,240 | -0.5% | 0.00% | – |
| Q2 2023 | $86,523 | -5.8% | 66,556 | +27.6% | 0.00% | – |
| Q1 2023 | $91,835 | -43.9% | 52,179 | 0.0% | 0.00% | – |
| Q4 2022 | $163,842 | -95.3% | 52,179 | -92.6% | 0.00% | -100.0% |
| Q3 2022 | $3,477,123 | +18.1% | 709,617 | -0.3% | 0.00% | 0.0% |
| Q2 2022 | $2,945,300 | -28.7% | 711,425 | +0.1% | 0.00% | -33.3% |
| Q1 2022 | $4,130,026 | -25.2% | 710,848 | -1.7% | 0.00% | 0.0% |
| Q4 2021 | $5,523,000 | -34.3% | 722,951 | -22.5% | 0.00% | -57.1% |
| Q3 2021 | $8,410,000 | -25.0% | 933,409 | -0.4% | 0.01% | -22.2% |
| Q2 2021 | $11,220,000 | -4.3% | 937,369 | +0.1% | 0.01% | -10.0% |
| Q1 2021 | $11,729,000 | -20.9% | 936,070 | -1.5% | 0.01% | -28.6% |
| Q4 2020 | $14,828,000 | +65.5% | 950,209 | +0.2% | 0.01% | +55.6% |
| Q3 2020 | $8,962,000 | +7.6% | 948,377 | -0.1% | 0.01% | +12.5% |
| Q2 2020 | $8,330,000 | +37.0% | 949,737 | -0.5% | 0.01% | +14.3% |
| Q1 2020 | $6,082,000 | -23.5% | 954,853 | +0.5% | 0.01% | -12.5% |
| Q4 2019 | $7,953,000 | +41.3% | 950,264 | +55.1% | 0.01% | +33.3% |
| Q3 2019 | $5,630,000 | +632.1% | 612,657 | +758.6% | 0.01% | +500.0% |
| Q2 2019 | $769,000 | +20.3% | 71,357 | +6.4% | 0.00% | 0.0% |
| Q1 2019 | $639,000 | -10.0% | 67,038 | +8.3% | 0.00% | 0.0% |
| Q4 2018 | $710,000 | -36.4% | 61,907 | -5.9% | 0.00% | 0.0% |
| Q3 2018 | $1,116,000 | +4.7% | 65,796 | -12.4% | 0.00% | 0.0% |
| Q2 2018 | $1,066,000 | -10.2% | 75,110 | +20.3% | 0.00% | 0.0% |
| Q1 2018 | $1,187,000 | +13.5% | 62,441 | -2.1% | 0.00% | 0.0% |
| Q4 2017 | $1,046,000 | +10.8% | 63,786 | +1.3% | 0.00% | 0.0% |
| Q3 2017 | $944,000 | +90.3% | 62,973 | +11.8% | 0.00% | 0.0% |
| Q2 2017 | $496,000 | +64.8% | 56,346 | -2.5% | 0.00% | – |
| Q1 2017 | $301,000 | +90.5% | 57,803 | +11.9% | 0.00% | – |
| Q4 2016 | $158,000 | -32.5% | 51,670 | +2.3% | 0.00% | – |
| Q3 2016 | $234,000 | -18.2% | 50,508 | +2.0% | 0.00% | – |
| Q2 2016 | $286,000 | +7.5% | 49,518 | +6.7% | 0.00% | – |
| Q1 2016 | $266,000 | -36.4% | 46,404 | +1.3% | 0.00% | – |
| Q4 2015 | $418,000 | +62.0% | 45,824 | 0.0% | 0.00% | – |
| Q3 2015 | $258,000 | -47.1% | 45,824 | +4.1% | 0.00% | -100.0% |
| Q2 2015 | $488,000 | -30.8% | 44,021 | -2.2% | 0.00% | 0.0% |
| Q1 2015 | $705,000 | +6.8% | 44,993 | +3.7% | 0.00% | 0.0% |
| Q4 2014 | $660,000 | +38.1% | 43,392 | -2.1% | 0.00% | 0.0% |
| Q3 2014 | $478,000 | -74.6% | 44,327 | -64.0% | 0.00% | -66.7% |
| Q2 2014 | $1,880,000 | +125.7% | 123,157 | +167.1% | 0.00% | +200.0% |
| Q1 2014 | $833,000 | +27.2% | 46,101 | -2.2% | 0.00% | 0.0% |
| Q4 2013 | $655,000 | +50.9% | 47,125 | +13.9% | 0.00% | 0.0% |
| Q3 2013 | $434,000 | +31.5% | 41,358 | -2.1% | 0.00% | 0.0% |
| Q2 2013 | $330,000 | – | 42,260 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |